Eli Lilly (LLY)
(Delayed Data from NYSE)
$734.97 USD
-20.94 (-2.77%)
Updated May 3, 2024 04:00 PM ET
After-Market: $735.54 +0.57 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LLY 734.97 -20.94(-2.77%)
Will LLY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Season: 3 Companies Boosting Guidance
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Company News for May 1, 2024
Other News for LLY
Eli Lilly: Great Time To Divest Before It Potentially Crashes
Amgen Could Become A Real Contender In The Obesity Market
16 out of 24 health care companies beat topline numbers this week- Earnings scorecard
SPMO: Heavy Into TMT Stocks After The March Reconstitution
Pharma R&D productivity seen improving for the first time in years - Deloitte